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Abstract: HIV infection has been recognized as a prothrombotic
now been proven by a large number of studies with a reported VTE frequency among HIV
patients ranging from 0.19% to 7,63 %/year. HIV infection is associated with a two to tenfold 
increased risk of venous thrombosis in comparison with a general population of the same age. Some 
risk factors demonstrated a strongest association with VTE such as, low CD4
in the presence of clinical AIDS, protein S deficiency, and protein C deficiency. Whereas o
factors  are  still  controversial  like  protease  inhibitor  therapy,  presence  of  active  opportunistic 
infections  and  presence of  antiphospholipid  antibodies, including  anticardiolipin antibodies and 
lupus anticoagulant. Physicians caring for HIV posi
treat  not  only  the  well-known  opportunistic  infections  and  malignancies  associated  with  this 
chronic  disease,  but  also  be  alert  to  the  less  well
Pulmonary embolism should be included in the differential diagnosis when patients with HIV/AIDS 
have unexplained dyspnea or hypoxemia. In younger individuals with VTE, especially men, without 
other identifiable risk factors for VTE, HIV should be considered. Because interactions b
warfarin and antiretrovirals is possible, health care providers should also be alert to the potential 
of dangerously high or low INRs when they are giving anticoagulants to patients with HIV infection 
who are undergoing antiretroviral therapy.
 
Introduction: Human immunodeficiency virus (HIV) 
infection results from one of two similar retroviruses 
(HIV-1  and  HIV-2)  that  destroy  CD4+  lymphocytes 
and impair cell-mediated immunity, affecting multiple 
organ  systems.  HIV  manifestation  ranges  from 
asymptomatic  carriage  to  the  acquired  immune 
deficiency  syndrome  (AIDS),  which  is  defined  by 
serious  opportunistic  infections  or  cancers.  In  2009, 
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HIV infection has been recognized as a prothrombotic condition and this association has 
now been proven by a large number of studies with a reported VTE frequency among HIV
patients ranging from 0.19% to 7,63 %/year. HIV infection is associated with a two to tenfold 
sis in comparison with a general population of the same age. Some 
risk factors demonstrated a strongest association with VTE such as, low CD4
+ cell count especially 
in the presence of clinical AIDS, protein S deficiency, and protein C deficiency. Whereas o
factors  are  still  controversial  like  protease  inhibitor  therapy,  presence  of  active  opportunistic 
infections and  presence of antiphospholipid  antibodies,  including anticardiolipin antibodies and 
lupus anticoagulant. Physicians caring for HIV positive patients should be able to recognize and 
known  opportunistic  infections  and  malignancies  associated  with  this 
chronic  disease,  but  also  be  alert  to  the  less  well-known  complications  such  as  thromboses. 
be included in the differential diagnosis when patients with HIV/AIDS 
have unexplained dyspnea or hypoxemia. In younger individuals with VTE, especially men, without 
other identifiable risk factors for VTE, HIV should be considered. Because interactions b
warfarin and antiretrovirals is possible, health care providers should also be alert to the potential 
of dangerously high or low INRs when they are giving anticoagulants to patients with HIV infection 
who are undergoing antiretroviral therapy. 
Human immunodeficiency virus (HIV) 
infection results from one of two similar retroviruses 
2)  that  destroy  CD4+  lymphocytes 
mediated immunity, affecting multiple 
organ  systems.  HIV  manifestation  ranges  from 
ge  to  the  acquired  immune 
deficiency  syndrome  (AIDS),  which  is  defined  by 
serious  opportunistic  infections  or  cancers.  In  2009, 
there were worldwide an estimated 33.3 million (31.4 
million -35.3 million) of adults and children living with 
HIV,  2.6  million  [2.3  million–
became newly infected with HIV, and 1.8 million (1.6
2.1 million) are the AIDS-related death among adults 
and  children.
1  Treatment  with  highly  active 
antiretroviral  therapy  (HAART)  has  successfully 
prolonged the life expectancy of HIV
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condition and this association has 
now been proven by a large number of studies with a reported VTE frequency among HIV-infected 
patients ranging from 0.19% to 7,63 %/year. HIV infection is associated with a two to tenfold 
sis in comparison with a general population of the same age. Some 
cell count especially 
in the presence of clinical AIDS, protein S deficiency, and protein C deficiency. Whereas other risk 
factors  are  still  controversial  like  protease  inhibitor  therapy,  presence  of  active  opportunistic 
infections  and  presence of antiphospholipid  antibodies, including  anticardiolipin  antibodies  and 
tive patients should be able to recognize and 
known  opportunistic  infections  and  malignancies  associated  with  this 
known  complications  such  as  thromboses. 
be included in the differential diagnosis when patients with HIV/AIDS 
have unexplained dyspnea or hypoxemia. In younger individuals with VTE, especially men, without 
other identifiable risk factors for VTE, HIV should be considered. Because interactions between 
warfarin and antiretrovirals is possible, health care providers should also be alert to the potential 
of dangerously high or low INRs when they are giving anticoagulants to patients with HIV infection 
there were worldwide an estimated 33.3 million (31.4 
35.3 million) of adults and children living with 
–2.8  million]  people 
became newly infected with HIV, and 1.8 million (1.6-
related death among adults 
Treatment  with  highly  active 
antiretroviral  therapy  (HAART)  has  successfully 
ancy of HIV-infected patientsMediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
Table 1: Main studies on VTE incidence in HIV patients. 
Author  Years studied  Population Size  VTE Incidence 
Jenkins
8  1991  243  3.29 % 
Laing
9  1996  728  0,96% 
Howling
10  1999  3792  1,07% 
George
11  1999  650  0,19-1,07% 
Sullivan
12  2000  42935  0,26% 
Saber
13  2001  4752  0,95% 
Saif
14  2001  131  7,63% 
Copur
15  2002  362  2,76% 
Fulz 
16  2004  13549 -514  2,0%- 1,6% 
Ahonkhai
17  1989 -2004  160  0,54% 
Malek 
18  1996-2004  6944  0.52 
Crum-Cianflone
19  1996-2007  465  3,7% 
Rasmussen
20  1995-2007  4333  8.0%-1,5%; norm pop 0,3% 
 
and infection with the human immunodeficiency virus 
is  increasingly  becoming  a  chronic  disease  in  the 
developed  world.
2.3  Improved  survival  has  been 
followed by an increased and anticipated prevalence of 
non-AIDS  related  conditions,  in  particular 
cardiovascular  disease  is  now  a  leading  cause  of 
morbidity and mortality among HIV-infected people.
4 
 
Epidemiology: Venous thromboembolism (VTE) is a 
common, serious disease with an estimated incidence 
rate in the general population of 1 per 1000 person-
years of observation.
5 Prevention and treatment of VTE 
are  gaining  attention  because  of  an  increase  in 
frequency, cost, and risk factors. Furthermore VTE is a 
potentially  preventable  disease  and  it  is  of  utmost 
importance  to  identify  individuals  in  high-risk 
populations  who  may  benefit  from  primary 
thromboprophylaxis.
6,7  HIV  infection  has  been 
recognized  as  a  prothrombotic  condition  and  this 
association has now been proven by a large number of 
studies. In fact many epidemiological studies reported 
on  the  occurrence  of  VTE  among  HIV-infected 
patients  with  a  frequency  ranging  from  0.19  to  7,63 
%/year.
8-20 These studies (Table 1) estimates that the 
overall  increase  of  the  risk  of  VTE  in  HIV-infected 
patients was 2-10-fold higher than expected in general 
population. However many trials were limited by small 
sample  size  and  a  lack  of  a  population  based 
comparison control, and mainly were conducted in the 
pre-HAART era.  Few studies were conducted in the 
more  recent  HAART  era.
8-20  Of  interest  recently 
Rasmussen found that the 5-year risk of VTE was 8.0% 
in  injecting  drug  users  (IDU)  HIV-infected  patients, 
1,5% in non-IDU HIV-infected patients and 0.3 % in 
the population comparison cohort.
20 
Although HIV-infected patients are at increased risk 
for venous thromboembolism little work has been done 
on  defining  the  exact  mechanisms  by  which  this 
phenomenon  occurs,  and  still  less  has  been  done  on 
evaluating  the  role  thromboprophylaxis  in  HIV-
infected  individuals.  Notably  the  2008  American 
College  of  Chest  Physicians  (ACCP)  guidelines  on 
antithrombotic and thrombolytic therapy are silent on 
this  subject.
7  Furthermore  there  are  some  important 
concerns about the therapy of HIV-related thromboses. 
The aim of this review is to provide an overview about 
the  venous  thromboembolism  in  HIV-infected 
individuals, trying to cover pathogenesis, prophylaxis 
and treatment issues. 
 
Risk Factors for Thromboembolism in Hiv-Infected 
Patients:  VTE  is  a  multicausal  disease  and  most 
commonly is the result of more than one “Hit”. The 
probability  of  developing  venous  thromboses  would 
depend on type and  number of risk  factors involved 
(Figure  1).  Many  established  factors  are  known  to 
increase  the  risk  of  VTE  in  general  population.
21 
Furthermore several specific factors are thought to be 
associated  with  VTE  in  patients  with  HIV.  For 
convenience  we  grouped  them  in  three  categories: 
those  regarding  the  host,  mainly  defining  a 
hypercoaglulable  state  and  endothelial  dysfunctions, 
those  regarding  the  HIV  diseases  state,  and  those 
regarding the therapy whether HAART or other.   
 
Host Risk Factors: 
Age: In the developed world advancing age is a well 
known risk for thrombosis in general population. The 
incidence  of  venous  thromboembolism  increase 
dramatically  as  the  population  ages,  from  0,001%  a 
year in childhood to nearly 1% a year in the elderly.
22 
Because  most  HIV  infected  people  are  relatively 
young,  their  risk  of  DVT  should  be  expected  to  be 
lower  than  the  overall  incidence.  Conversely  many 
studies  reported  that  HIV-infected  patients  had  a 
median age of 40 at time of venous thromboembolism 
that is 20 years younger than the median age of non 
infected  patients.
12,15  Furthermore  patients  younger 
than  50  years  with  HIV  had  a  significantly  higher 
incidence  rate  of  VTE/year  compared  with  age-
matched  healthy controls.
23 HIV-infected patient are in 
fact  older  than  their  chronological  age  and  they
 Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
 
Figure 1: Multi-factorial etiology of HIV-related venous thromboembolism. AT, antithrombin; sTM, soluble thrombomodulin; TFPI, tissue 
factor pathway inhibitor; v-WF, von Willebrand Factor; PAI-I, plasminogen activator inhibitor-1; tPA, tissue plasminogen activator. Stronger 
risk factors for VTE are listed in bold. 
 
experience  the  so-called  “Premature  Aging”.  In  this 
immunological  ageing  the  immune  system  has 
persistent  defects  even  after  years  of  treatment 
mediated viral suppression. Many are similar to those 
seen in normal ageing, but they occur at an earlier age 
than  normal.
24  Persistent  abnormalities  include  low 
CD4:CD8  ratio,  low  naïve:memory  cell  ratio, 
expansion of CD28− effector T cells, reduced T cell 
repertoire,  and  reduced  responsiveness  to  vaccines. 
Most of these abnormalities are seen only in patients 
who  start  treatment  in  late  stage  disease  (CD4  nadir 
<200 cells).
25 The heightened risk for premature aging 
is  also  the  result  of  residual  immunodeficiency  and 
inflammation.
26 
 
Intravenous  Drug  Use:  The  intravenous  use  of 
recreational  drugs  is  associated  with  considerable 
morbidity,  a  significant  proportion  of  which  may  be 
from the drug itself.
27 Intravenous drug use has been 
recently  identified  as  an  important  cause  of 
community-acquired  VTE  in  young  adults.
28  In  a 
recent elegant paper Rasmussen first show the impact 
of    intravenous  drug  use  on  risk  Of  VTE  in  HIV-
infected  patients.
20  This  study  found  that  the  risk  of 
VTE was nearly 15 times higher in IDU HIV-infected 
patients that in non IDU HIV-infected patients.  
 
Hypercoagulable  State:  Protein  S  Deficiency:  It  is 
currently accepted that protein S (PS) deficiency is a 
significant  contributor  to  the  pro-coagulant  nature  of 
HIV infection. In fact protein S deficiency is the most 
consistently  observed  coagulation  abnormality 
observed  in  HIV-infected  patients,  with  a  reported 
prevalence ranging from a 27% to a 76%, with a 12% 
of those patients having a venous thromboembolism.
29-
32 PS deficiency in HIV-positive patients is probably 
multi-factorial  and  the  frequency  of  this 
alteration/deficiency has led to an extensive pursuit of 
potential  mechanism.  Type  III  PS  deficiency  is  the 
most common abnormality found and characterized by 
a normal total protein S level with a decrease in both 
free  protein  S  and  functional  protein  S  activity.
33 
Decreased  synthesis  by  the  endothelial  cells, 
hepatocytes  and  megakariocytes  injured  in  HIV 
infection has  been  proposed.
30  A  positive  correlation 
between antibodies to PS and low levels of circulating 
free antigen has also been noted in symptomatic HIV-
infected patients.
34 Other authors suggested that tumor 
necrosis-factor-alpha (TNF-α) can lower the  levels of 
active  protein  S  down-regulating  the  protein  S Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
synthesis in the endothelial cells.
35 Another publication 
showed how the occurrence of PS deficiency might be 
linked to the presence of antiphospolipid antibodies.
36 
Protein C Deficiency: The relationship between protein 
C deficiency and VTE in HIV infection is not as clear 
as  that  of  protein  S  deficiency,  with  a  prevalence 
ranging from 0 to 14%. However in one study a high 
prevalence of protein C deficiency was found in HIV 
patients who had VTE without other noted risk factors 
for venous thromboembolism.
31 The mechanism of PC 
deficiency in HIV infected persons is multi-factorial, 
including altered synthesis and metabolism as well as 
low-grade  disseminated  intravascular  coagulation 
(DIC) with consumptive coagulopathy.
37 
Antithrombin Deficiency: There is no direct evidence 
of HIV infection leading to Antithrombin deficiency. 
Acquired  AT  deficiency    frequently  occurs  in  the 
course of HIV disease as a consequence of associated 
conditions that cause decreased protein synthesis (liver 
diseases  eg  HCV  coinfections  and  malnutrition), 
protein-losing  nephropathies  or  enteropathies, 
consumptive  states  (malignancy,  DIC,  surgery). 
Nevertheless cases of AT deficiency in HIV patients 
who  experienced  thrombotic  events  have  been 
reported.
14,38,39 
Antiphospholipid  And  Lupus  Anticoagulant 
Antibodies:  The  antiphospholipid syndrome (APS)  is 
an autoimmune disease associated to the appearance of 
two  main  circulating  auto-antibodies,  anticardiolipin 
antibodies (ACA) and lupus anticoagulant (LA). The 
frequency of APS in the general population is 2-4%, 
and is clearly linked to increased risk of venous and 
arterial thrombosis.
40 ACA  have been reported in HIV-
infected patients with a prevalence ranging from 7% to 
94%.
41  However  there  are  both  reports  of  no 
association
42,43 and positive association between having 
positive  ACA  and  VTE  in  HIV+  patients.
44,45  LA  is 
much more variable in frequency and manifestation in 
HIV+ patients. The incidence ranging from 0% to 72% 
but  no  pathogenic  correlation  was  found  with 
thromboses  in  two  large  series  of  HIV  patients[]
44,45 
even if some case  reports are found in the literature.
46 
Actually is thought that LA activity in those patients 
might  be  an  epiphenomenon  secondary  to  chronic 
immune stimulation in HIV infection. 
Tissue  Factor:  Recently  Funderburg  et  al
47  found 
dramatically  higher  frequencies  of  monocytes 
expressing  tissue  factor  (TF)  in  fresh  blood  samples 
from  HIV-infected  persons  than  in  samples  from 
uninfected controls. They postulated  that a variety of 
bacterial  toll-like  receptor  (TLR)  ligands,  such  as 
peptidoglycans,  lipopolysaccharide  (LPS),  and 
flagellins, are translocated through the damaged gut in 
chronic  HIV  infection  and  may  drive  immune 
activation (in addition to HIV viral Replication)  and 
monocyte  TF  expression  in  this  setting.
48  The 
relevance of increased TF expression in HIV infection 
is  underscored  by  the  high  levels  of  D-dimers  in 
plasma and by the correlation between TF expression 
and  D-dimer  levels.    HIV  replication  and  systemic 
translocation of microbial products from the damaged 
gut, and the subsequent immune activation, contribute 
to a procoagulant state in HIV-infected patients that is 
due, at least in part, to increased surface expression of 
TF on circulating monocytes.
48 
Microparticles: The term “microparticles” (MP) refers 
to a small (< 1mµ) membrane vesicles released from 
activated  or  apoptotic  cells.
49  The  MPs  may  be 
generated  from  endothelial  cells,  vascular  smooth 
muscle cells, platelets, tumor cells and from apoptotic 
CD4+ lymphocytes.
50 In healthy individuals, very low 
levels  of  MPs  are  present  in  platelet-free  plasma, 
conversely elevated levels have been identified in HIV-
positive patients, but there is no clear evidence that this 
causes a rise in the risk of VTE.
51 
Homocysteine:  Mild  to  moderate 
Hyperhomocysteinemia (HHcy) is relatively common 
in  HIV-infected  individuals,  especially  those  using 
cART, with a prevalence ranging from 11 to 29%.
52,53 
Prospective cohort studies and an interventional trial in 
general population
 have estimated the increase in the 
risk of recurrence associated with raised homocysteine 
concentrations  to  be  about  1  to  5-fold.
54,55  However, 
because  vitamin  supplementation  (which  reduces 
homocysteine  concentrations)  does  not  affect  rate  of 
recurrence,  a  causal  relation  between 
hyperhomocysteinemia and venous thrombosis remain 
uncertain.
56 HHcy is frequently present in HIV-patients 
without causing clinical manifestation suggesting that 
it may not be sufficient alone causing VTEs. However 
HHcy may add an additional risk among patients with 
other risk factors for venous clots.    
Endothelial  Dysfunction:  Many  studies  showed  a 
strong  association  between  endothelial  cells 
abnormalities  and  VTE  in  general  population.
57-59 
Under  normal  conditions  endothelial  cells  exert  a 
vasodilatory, antiplatelet and local fibrinolytic tone that 
prevents  platelet  adhesion,  leukocyte  attachment,  as 
well as blood coagulation.     
A  non-thrombogenic  endothelial  surface  is 
maintained  through  a  number  of  mechanisms, 
including the production of thrombomodulin (TM) (an 
activator of anticoagulant protein C), the expression of 
heparan  and dermatan sulphate (which accelerate the 
thrombin-inhibitory activity of antithrombin III and of 
heparin  cofactor  II),  the  constitutive  expression  of 
tissue factor pathway inhibitor (TFPI)(an inhibitor of 
tissue  factor),  and  the  local  production  of  tissue 
plasminogen  activator  (tPA)  and  urokinase-type 
plasminogen  activator  (uPA),  that  are  the  main Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
effectors of physiologic fibrinolysis. Crucial to many 
of the antithrombotic activities of endothelium are the 
synthesis  of  prostacyclin  (PGI2)  and  of  nitric  oxide 
(NO).[60]  In  the  context  of  VTE,  a  dysfunctional 
venous endothelium may express increased amounts of 
P-selectin ,von Willebrand factor (vWF), tissue factor 
(TF),  plasminogen  activator  inhibitor-1  (PAI-1),  and 
factor V, all of which may promote blood clotting and 
participate  in  the  development  of  a  thrombus.
61  It  is 
now  well  estabilished  that  the  endothelium  could  be 
activated  directly  by  HIV  virus.  In  fact  multiples 
studies reported the role of HIV in causing endothelial 
dysfunction.
62,63 
P-Selectin: In a recent study P-selectin was found in 
HIV-infected  patients  to  be  independently  and  most 
strongly associated with venous thrombosis.
64 Stored in 
endothelial  cells  and  platelet  granules,  P-selectin 
interacts  with  its  receptor  to  promote  a 
hypercoagulable  environment  by  inducing  the 
generation  of  prothrombotic  microparticles  from 
leukocytes and upregulation of tissue factor expression 
on monocytes.
65 Prospective studies in HIV-uninfected 
participants with malignancies have demonstrated that 
P-selectin is significantly elevated in patients with an 
impending or acute VTE. Furthermore, P-selectin has 
been shown to have comparable diagnostic value to D-
dimer in patients with confirmed DVTs.
66 
Miscellaneous  Factors  of  Haemostasis:  Various 
markers  of  endothelial  cell  damage  such  as  von 
Willebrand  factor  (vWF),  soluble  thrombomodulin 
(sTM),  adhesion  molecule  E-selectin,  tissue-type 
plasminogen  activator  (tPA),  plasminogen  activator 
inhibitor  (PAI-1),fibronectin,  angiotensin-converting 
enzyme (ACE), and endothelin have been shown to be 
increased in the course of HIV-1 infection.
67,68 HC II 
deficiency was significantly more pronounced in AIDS 
patients  compared  with  HIV  patients  and  possible 
reason  for  HC  II  deficiency  could  be  the  decreased 
synthesis,  enhanced  proteolysis  or  consumption.[69] 
However  no  paper  has  shown  a  direct  correlation 
between  the  low  levels  of  HC  II  in  HIV-positive 
patients and VTE. The secretion of tPA, (PAI-1), sTM, 
and vWF creates alterations in the coagulation cascade 
and could predispose to thrombosis.
70-73 Furthermore, 
HIV  gp120  could  induce  tissue  factor  expression  in 
vascular SMCs, which may have potential effects on 
the  arterial  wall  thrombogenicity.
74  Anyway  a  link 
between in vitro findings and clinical events in HIV 
patients is still lacking. 
 
Viral Risk Factors:  
CD4+ Cell Count: The severity of the HIV infection 
appears to be of significance in association with VTE. 
In fact several studies confirmed that there is a higher 
incidence  of  venous  thrombosis  in  patients  with  low 
CD4  counts.
12,37,75,76  In  particular  although  the  CD4 
nadir and most recent CD4 count were both predictive 
in  the  univariate  models,  the  strongest  predictor  in 
multivariate models was the CD4 cell count at the time 
of the VTE.
14,19,77,78 Although the frequency of VTE is 
higher in the presence of lower CD4
+ cell counts, there 
are  reports  of  thrombosis  occurring  with  CD4
+  cell 
counts as high as 800 cells/mm
3, suggesting that the 
risk  of  thrombosis  is  not  completely  confined  to 
patients  with  end-stage  disease.
19  The  correlation 
between CD4 count and the risk for the development of 
thromboses  may  be  related  to  an  increasing 
hypercoagulable state found with progressive immune 
suppression  and  HIV  disease  progression.  Various 
studies have documented that the abnormalities in pro- 
and anticoagulant factors, and as described previously,  
worsens  as  the  disease  progresses,  swinging    the 
pendulum in favor of thrombosis.
53,79,80 
 
Viral Load: Another indicator of high disease burden 
of HIV infection is viral load, also known as HIV RNA 
level. Low CD4
+ cell counts and high viral loads are 
predictive  of  progression  of  HIV  and  typically 
complement  each  other  in  the  absence  of  treatment. 
One  group  of  authors  concluded  that  a  higher  viral 
load, and lower CD4
+ cell count, was associated with a 
higher risk of thrombosis,
19 conversely others found no 
correlations.
14 
 
Opportunistic  Infection:  In  spite  of  the  efficacy  of 
HAART, HIV-positive individuals are at the greatest 
risk for developing opportunist infections depending to 
their immunologic status. So the concomitant presence 
of advanced HIV disease and opportunistic infections 
appears  to  be  an  additional  risk  factor  for 
Thrombosis.
8,13,14,76,79 
VTE  is  most  commonly  reported  with 
Cytomegalovirus  and  Pneumocystis  jiroveci 
pneumonia  (PCP)  and  Mycobacteriumavium-
intracellulare.
79,80 
 
Cytomegalovirus: Cytomegalovirus active infection is 
a  well-established  cause  of  thrombosis  and  several 
case-studies described active cytomegalovirus infection 
in  patient  with  VTE  in  general  population.
81-86 
Regarding  HIV-infected  patients  active 
cytomegalovirus infection has decreased substantially, 
in current HAART era, to less than 6 cases/100 person-
years.
87  In  one  study  it  was  associated  with  a 
procoagulant  state  independently  of  stage  of  HIV 
disease.
88  The  reported  frequency  of  VTE  in  the 
presence  of  cytomegalovirus  in  HIV-positive 
individuals is approximately 9.8%, with the majority of 
thrombosis  associated  with  gastrointestinal-related 
disease.
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Pneumocystis  Jiroveci  Pneumonia:  Many  authors 
reported the presence of active PCP during a VTE in 
HIV-infected  patients.
10,14,23,79  VTE  associated  with 
PCP may be secondary to the hypercoagulable state in 
patients  with  AIDS.  In  fact  Pneumocystis  jiroveci 
pneumonia patients with HIV have been shown to have 
an high rate of concurrent antiphospholipid syndrome 
that  may  increase  the  risk  for  developing  VTE.
89 
Venous  thromboembolism,  specifically  pulmonary 
embolism,  in  this  population  may  remain 
underdiagnosed because of similar signs and symptoms 
of  presentation  between  pulmonary  embolism  and 
PCP.
90 
 
Mycobacterium  Tuberculosis  and  Intracellular 
mycobacterium  Avium:  Mycobacterium-avium-
intracellulare  and  Mycobacterium  tuberculosis  may 
induce  anticardiolipin  antibodies  and  a 
hypercoagulable  state.  Although  anticardiolipin 
antibodies  are  found  in  these  patients,  a  clear  
relationship  with  the  appearance  of  thromboembolic 
complications was not demonstrated.
91Declining levels 
of  anticardiolipin  antibodies  seem  to  occur  after  the 
initiation  of  effective  treatment  of  underlying 
infection.
47,92  Mycobacterium  tuberculosis  is  able  to 
activate  macrophages  directly  and  induces  them  to 
produce cytokines,  especially TNF-α, IL-1 and IL-6. 
TNF-α  and  IL-1  blocks  the  protein  C  anticoagulant 
pathway  and  can  elicit  tissue  factor  production  on 
endothelium and monocytes.
93 IL-6 can also stimulate 
new  platelets  formation  which  have  increased 
sensitivity  to  thrombin  activation  and  increased  pro-
coagulant  activity.  The  prevalence  of  VTE  in 
Tuberculosis  patients  is  ranging  from  0.6%  to  3%, 
while  the  prevalence  of  VTE  in  patients  with 
coexisting HIV and tuberculosis is unknown.
94,95 
 
HIV-associated  Malignancy:  The  risk  of  VTE  in 
patients  with  cancer  varies  considerably  between 
patients  and  even  within  an  individual  patient  over 
time. Estimates ranging from  15 to 30 % have  been 
reported.
96  It  is  well-known  how  patients  with  no 
identifiable risk factors who develops DVT may have 
an  underlying  occult  malignancy.
97  People  with  HIV 
infection  and  AIDS  have  an  elevated  cancer  risk.
98 
Compared  with  the  general  population,  HIV-infected 
individuals have a 3640-fold increased risk of Kaposi 
sarcoma (KS), a 77-fold increased risk of non-Hodgkin 
lymphomas  (NHL),  and  a  six-fold  increased  risk  of 
cervical  cancer.
99  These  malignancies  are  AIDS-
defining  cancers,  based  on  the  Centers  for  Disease 
Control and Prevention (CDC) definition of AIDS.
100 
HIV-infected people also have an increased risk of a 
number of non-AIDS-defining cancers, including some 
associated  with  co-infections  (eg,  anal  and 
oropharyngeal cancers associated with HPV infection, 
liver cancer associated with infection with hepatitis B 
and C viruses, and Hodgkin lymphoma associated with 
Epstein–Barr virus infection).
101 Kaposi Sarcoma (KS) 
is the most common malignancy reported in literature 
associated with VTE in HIV-patients.  Several reviews 
regarding    thromboembolism  in  patients  with  KS  in 
HIV-infected  patients  have  reported  an  incidence  of 
thrombosis  ranging  from  9.3%  to  20%.
13,23,102  The 
remaining malignancies were reported as single cases 
of  primary  CNS  Lymphoma,  B-cell  non-Hodgkin 
lymphoma,  Hodgkin  disease,  prostate  cancer,  anal 
cancer, colon cancer.
13,19,23 
 
Drugs Risk Factors:  
HAART: HAART and in particular the use of protease 
inhibitors  (PI)  have  been  associated  with  thrombotic 
events.
11,12,31,32 PI are thought to interfere with hepatic 
metabolism, specifically cytochrome P450 metabolism, 
and  regulation  of  thrombotic  proteins.  This  may 
ultimately cause a prothrombotic state in HIV-infected 
individuals  and  therefore  increase  the  risk  of  a 
thrombotic  episode.  Otherwise  they  may  either 
downregulate the anticoagulant effect within the body 
or  generate  endothelial  or  platelet  dysfunction.
14 
Consistent  data  exist  connecting  protease  inhibitors 
with lipodystrophy, and  HIV-positive individuals with 
fat  redistribution  may  be  at  increased  risk  for 
developing  an  abnormal  coagulation  profile,  such  as 
increased  fibrinogen,  D-dimer,  plasminogen  activator 
inhibitor-1, or protein S deficiency.
103 Despite limited 
data, protease inhibitors  indinavir and saquinavir, have 
been associated  with an increased risk of VTE in the 
HIV-positive  population,
11,23,104,105  however  a  recent 
publication  could  prove  no  such  association, 
suggesting that the association between HAART and 
risk of thrombosis may arise from mutual associations 
with other risk factors, in particular advanced disease.
19 
 
Megestrol:  Megestrol  acetate  is  a  synthetic,  orally 
active,  progestational  agent,  used  widely  in  the 
treatment of metastasic breast cancer. It has also been 
reported  to  stimulate  appetite  and  weight  gain  in 
patients  with AIDS-related anorexia  and/or cachexia. 
In these groups of patients thromboembolic phenomena 
as adverse events potentially related to megestrol have 
been reported.
106,107 
 
Clinical  Presentation:  Clinicians  should  be  alert  to 
unprovoked thrombosis as a possible complication of 
AIDS and consider this in the differential diagnosis of 
patients  with  HIV  infection.  It  is  possible  that  the 
incidence of thromboembolic disease in those patients 
have  been  underestimated  either  due  to  the  clinical Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
picture  mimicking  opportunistic  infections  (e.g., 
opportunistic  pulmonary  infection  vs.  PE)  or  not 
considering the less well-known complication such as 
venous  thromboembolism.
108  The  clinical  appearance 
and distribution of thrombosis reported in the literature 
is similar to non HIV-patients.
14,19,23 Most commonly 
thromboses  involve  the  popliteal  and  femoral  veins 
followed  by  pulmonary  emboli.[10,36]  In  addition, 
abdominal involvement may occur as portal or splenic 
vein  thromboses.
109,110  HIV-infected  persons  may 
experience recurrences with an incidence of recurrence 
rate ranging from 8% to 15 %.
12 
 
Pregnancy:  Venous  thromboembolism  (VTE),  in 
women  during  pregnancy  and  puerperium,  has  been 
described  in  literature  with  an  incidence  of 
approximately  1–2  in  1000  pregnancies.  Women  are 
five  times  more  likely  to  develop  VTE  during 
pregnancy  or  puerperium  compared  to  non-pregnant 
women. A recent study reported the annual incidence 
of VTE in HIV-positive women during puerperium of 
313/1000 person-years (95% CI 65–915).
111 According 
to this finding, HIV-positive pregnant women are 120-
fold  more  likely  to  develop  VTE  than  HIV-positive 
controls,
12  whereas  the  risk  is  157-fold  higher 
compared to HIV-negative pregnant women.
111 
 
Management:  The  2008  ACCP  guidelines  on 
antithrombotic  and  thrombolytic  therapy  do  not 
mention HIV-infected patients. Nevertheless clinicians 
dealing  with  HIV  must  be  aware  that  this  high  risk 
population  needs  particular  attentions  regarding 
antithrombotic  prophylaxis  and  therapy  looking  at 
them  in  the  same  way  as  it  would  be  for  patients 
suffering  from  cancer.  The  management  of  proven 
VTE in HIV-infected patients should be the same as 
for  the  non  HIV-patients,  including  long-term 
prophylaxis  with  low  molecular  weight  heparin  and 
warfarin for patients with recurrent thrombosis.   
Antiretroviral therapy and warfarin drug interaction: 
Because of an increased risk of thromboembolism in 
patients with HIV/AIDS and the increasing longevity 
of  the  HIV-infected  population  receiving  effective 
antiretroviral therapy, more HIV-positive patients will 
be  receiving  in  the  future  concomitant  oral 
anticoagulant and antiretroviral therapy.  
The  interaction  between  antiretroviral  agents  and 
other  medications  has  been  widely  described.
112 
Interactions  between  warfarin  and  antiretrovirals  is 
possible, given the influence of many antiretrovirals on 
CYP2C9 the enzyme responsible for the metabolism of 
the more active S-enantiomer of warfarin.
113 
Among  the  antiretrovirals,  interactions  involving 
non-nucleoside  reverse  transcriptase  inhibitors 
(NNRTIs) and protease inhibitors (PIs) with warfarin 
are  most  likely  to  occur.  Inhibition  or  induction  of 
metabolism requiring warfarin dosage adjustment may 
be  observed,  depending  on  the  specific  antiretroviral 
drug.    Among  the  NNRTIs,  induction  of  warfarin 
metabolism  is  likely  with  nevirapine.  Inhibition  of 
warfarin  metabolism  may  occur  with  efavirenz, 
delavirdine, or etravirine, but more evidence is needed 
to  characterize  the  nature  and  onset  of  these 
interactions.    Interactions  involving  ritonavir-boosted 
PIs  are  most  frequent  when  warfarin  is  initiated  in 
patients  receiving  concurrent  efavirenz  therapy.  It 
seems prudent to base warfarin dosage adjustments on 
International Normalized Ratio (INR) response rather 
than empirically beginning with a lower warfarin dose. 
Similarly,  INR  response  should  be  used  to  guide 
warfarin dosage requirements in patients on nevirapine, 
nelfinavir,  lopinavir/ritonavir,  or  other  ritonavir-
boosted  PIs  rather  than  starting  with  higher  baseline 
doses.
114-117 
Health  care  providers  should  be  alert  to  the 
potential for dangerously high or low INRs when they 
are  giving  anticoagulants  to  patients  with  HIV 
infection  who  are  undergoing  antiretroviral  therapy. 
Perhaps alternative forms  of anticoagulation, such as 
low-molecular-weight  heparin  (LMWH),  should  be 
considered  in  some  cases  in  the  HIV-infected 
population  receiving  antiretroviral  therapy,  given  the 
absence of compliance in some HIV-affected subjects.  
LMWH  should  be  a  safer  choice  in  those  patients, 
always keeping in mind that HIV infection may be an 
independent risk factor for the development of heparin-
induced thrombocytopenia (HIT).
118 Lastly the timing 
of administration of warfarin and certain antiretroviral 
agents should be staggered. 
 
Conclusions:  Currently  available  epidemiological 
evidence  suggests  that  chronic  HIV  infection  is 
associated  with  a  two  to  tenfold  increased  risk  of 
venous  thrombosis  in  comparison  with  a  general 
population  of  the  same  age.  Some  risk  factors 
demonstrated a strongest association with VTE such as 
like  a  diagnosis  of  AIDS,  low  CD4
+  cell  count 
especially in the presence of clinical AIDS, protein S 
deficiency,  and  protein  C  deficiency.  (Figure  2) 
Whereas other risk factors are  still controversial like 
protease  inhibitor  therapy,  presence  of  active 
opportunistic  infections  and  presence  of 
antiphospholipid  antibodies,  including  anticardiolipin 
antibodies  and  lupus  anticoagulant.  With  this 
understanding, appropriate prophylactic measures can 
be  instituted,  which  may  include  universal  VTE 
prophylaxis with oral anticoagulants or low-molecular 
weight  heparin  on  hospitalization  and  for  high-risk 
outpatients. Physicians caring for HIV positive patients 
should be able to recognize and treat not only the well- Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
 
Figure 2: Diagram summarizing the pathogenesis of HIV-related VTE. HIV, human immunodeficiency virus; LPS, lipopolysaccharide; 
TLR, toll-like receptor; AT, antithrombin; ACA, anticardiolipin antibodies; LA, lupus anticoagulant; TF, Tissue Factor; TNF-a, tumor 
necrosis factor alpha; IL-6 , interleukin six; hsCRP, high-sensitivity C-reactive protein; MCP1, monocyte chemotactic protein-1;  sTM, 
soluble thrombomodulin; TFPI, tissue factor pathway inhibitor; v-WF, von Willebrand Factor; PAI-I, plasminogen activator inhibitor-1; tPA, 
tissue plasminogen activator 
 
known  opportunistic  infections  and  malignancies 
associated with this chronic disease, but also be alert to 
the less well-known complications such as thromboses. 
Pulmonary  embolism  should  be  included  in  the 
differential  diagnosis  when  patients  with  HIV/AIDS 
have unexplained dyspnea or hypoxemia. In younger 
individuals  with  VTE,  especially  men,  without  other 
identifiable  risk  factors  for  VTE,  HIV  should  be 
considered.  
Finally new well-designed case control studies are 
needed  to  answer  several  open  questions:  Do 
traditional factors associated with increased VTE risk 
have the same impact in HIV patients? Does HAART 
contribute  to  VTE  risk  in  HIV  and  How?  Are 
traditional screening methods applicable in HIV? Are 
traditional VTE risk management strategies applicable 
in HIV? 
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